Genzyme executives today rolled out positive data from a one-year extension study of its pivotal Phase III trial that gives the company some boasting rights for a drug that demonstrated a durable response in most patients.
Sanofi ($SNY) CEO Chris Viehbacher paid tribute to his Genzyme unit's MS drug candidate Lemtrada as the FDA accepted the company's application for its U.S. approval.
This morning Sanofi put out the word that the FDA has accepted the biologics application for Genzyme's multiple sclerosis drug hopeful Lemtrada, fanning some flames of late-stage excitement for a company that still doesn't think its R&D efforts are fully appreciated among the ranks of Wall Street analysts.
Sanofi's Genzyme group in Boston put up a new set of data to back its bid to make Lemtrada a leading therapy for multiple sclerosis.
Sanofi's critics have launched a new offensive. After months of protesting yielded big reductions in the French drugmaker's layoff plans in its home country, those less-than-pleased with Sanofi ($SNY) are zeroing in on its decision to swap cheap Campath for the (presumably) much pricier, soon-to-be-approved multiple sclerosis drug Lemtrada.
Neither strike threats nor angry government ministers have stopped Sanofi from pushing ahead with deep job cuts in France. The French newspaper Le Figaro reports that the pharma giant will unveil a cutback of 1,500 to 2,500 jobs on September 25.
The speculation about Genzyme's Campath is over. The company, now a unit of Sanofi, is pulling the plug. Why? To prepare the way for Lemtrada, a multiple sclerosis treatment that is, essentially, Campath by another name.
Sanofi is on track to find out whether its $20 billion deal for Genzyme will pay off with a near-term drug approval. The pharma giant says that Genzyme has submitted applications for the MS drug Lemtrada in both the U.S. and Europe. Bayer is partnered on the program.
Genzyme continues to build the large late-stage data package for teriflunomide, an oral multiple sclerosis drug that the company and its owner, Sanofi, are developing to compete in the blockbuster market for MS therapies that are swallowed rather than injected.
Sanofi has rolled out a fresh set of late-stage Lemtrada (alemtuzumab) data demonstrating its superiority to Rebif in a head-to-head matchup for multiple sclerosis.